MedTrace Logo

Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)

NCT02554344 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2026-01-30

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, feasibility, and regression rate of using curcumin in patients with Cervical Intraepithelial neoplasias (CIN3). The secondary objectives of this study is to evaluate patients with CIN3 for the presence of high-risk Human papillomavirus (HPV) and to perform an inflammatory panel on dysplasia biopsies from patients with CIN3 to determine which factors play a role in persistence of CIN3.

Conditions

  • Cervical Intraepithelial Neoplasia

Interventions

DRUG

Curcumin

Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Carolyn Matthews, MD · Baylor Research Institute/Texas Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-22
Primary Completion
2017-07-11
Completion
2017-07-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02554344 on ClinicalTrials.gov